MedTrace Logo

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

NCT06088979 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2026-04-23

No results posted yet for this study

Summary

Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.

Conditions

  • Thyroid Eye Disease

Interventions

DRUG

TOUR006 - 20 MG

TOUR006 20 MG

OTHER

Placebo

Placebo

DRUG

TOUR006 - 50 MG

TOUR006 - 50 MG

Sponsors & Collaborators

  • Tourmaline Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Tourmaline Bio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-19
Primary Completion
2026-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • France
  • Italy
  • Jordan
  • Latvia
  • New Zealand
  • Puerto Rico
  • Slovakia
  • South Korea
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06088979 on ClinicalTrials.gov